The Second Methylation in Psilocybin Biosynthesis Is Enabled by a Hydrogen Bonding Network Extending into the Secondary Sphere Surrounding the Methyltransferase Active Site. - Hudspeth J; Rogge K; Wagner T; Müll M; Hoffmeister D; Rupp B; Werten S. (2024)

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial. - Lee J; Philip K; Wijeysundera DN; Clarke H; Pritlove C; Katz J; Ritvo P; Goel A; Husain MI; Ladha KS. (2024)

Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms - Hodge A; Forsyth A; Noorani T; Muthukumaraswamy S; Rolleston A; McHugh P. (PsyArXiv, 2024)

Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits - Pasquini L; Vohryzek J; Escrichs A; Sanz Perl Y; Ponce-Alvarez A; Idesis S; Girn M; Roseman L; Mitchell JM; Gazzaley A; Kringelbach M; Nutt DJ; et al. (bioRxiv, 2024)

Amid magic and menace: psychiatrists' attitudes to psilocybin therapy. - Gribben A; Burke T; Harrington C; Husein A; Murnane KS; Hendricks PS; Tobin K; Ivers JH; Thuery G; Harkin A; Kelly JR. (2024)

PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study) - Imperial College London (ClinicalTrials.gov, 2024)

Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies. - Barstowe A; Kajonius PJ. (2024)

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use. - Syed OA; Petranker R; Fewster EC; Sobolenko V; Beidas Z; Husain MI; Lake S; Lucas P. (2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. - Valdez T; Patel V; Senesombath N; Hatahet-Donovan Z; Hornick M. (2024)

Australian psychologists' attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling. - Negrine JJ; Puljević C; Ferris J; Liknaitzky P; Perlman C; Piatkowski T. (2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial - Aday JS; McAfee J; Conroy DA; Hosanagar A; Tarnal V; Weston C; Scott K; Horowitz D; Harte SE; Pouyan N; Glynos NG; Baker AK; et al. (PsyArXiv, 2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial (PsyArXiv, 2024)

Pyramidal cell types and 5-HT2A receptors are essential for psilocybin’s lasting drug action - Shao L; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu R; Woodburn SC; Bilash OM; Kim H; et al. (bioRxiv, 2024)

Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour. - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (2024)

Optimized psilocybin production in tryptophan catabolism-repressed fungi. - Janevska S; Weiser S; Huang Y; Lin J; Hoefgen S; Jojić K; Barber AE; Schäfer T; Fricke J; Hoffmeister D; Regestein L; Valiante V; et al. (2024)

[Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.] - Forte V; Shaughnessy AF; Kurotschka PK. (2024)

Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats. - Jeanblanc J; Bordy R; Fouquet G; Jeanblanc V; Naassila M. (2024)

Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial. - Swanson LR; Jungers S; Varghese R; Cullen KR; Evans MD; Nielson JL; Schallmo MP. (2024)

Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. - Adams DR; Allen H; Nicol GE; Cabassa LJ. (2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts - Luoma JB; Wilson-Poe A; Pertl K; Hoffman K; Bazinet A; Stauffer C; McCarty D; Korthuis P. (PsyArXiv, 2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts (PsyArXiv, 2024)

Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials. - Aghajanian S; Shafiee A; Parvizi Omran S; Rezaei Nejad A; Jafarabady K; Kohandel Gargari O; Rajai S; Mohammadi I; Bahrami Babaheidari T; Bakhtiyari M. (2024)

A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study - Filament Health Corp. (ClinicalTrials.gov, 2024)

A narrative exploration of psilocybin's potential in mental health. - Min H; Park SY; Park J; Na S; Lee HS; Kim T; Ham J; Park YT. (2024)

Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner. - Wiens KR; Brooks NAH; Riar I; Greuel BK; Lindhout IA; Klegeris A. (2024)

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms - Imperial College London (ClinicalTrials.gov, 2024)

Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (bioRxiv, 2024)

Expert recommendations for Germany's integration of psychedelic-assisted therapy. - Perez Rosal SR; La Torre JT; Birnkammer S; Chernoloz O; Williams MT; Faber SC. (2024)

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada. - Kim K; Yusuf A; Sud A; Persaud N; Kirubarajan A; Moller M; Lloyd T; O'Neill B. (2024)

Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis. - Rogge K; Wagner TJ; Hoffmeister D; Rupp B; Werten S. (2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics - Majic T; Schmidt TT; Gröticke A; Gasser P; Richards WA; Riemer TG; Evens R. (PsyArXiv, 2024)

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin - Mallaroni P; Singleton P; Mason NL; Satterthwaite TD; Ramaekers JG. (bioRxiv, 2024)

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study. - Jones G; Lowe MX; Nayak S; Sepeda N; Kettner H; Carhart-Harris R; Jackson H; Garcia-Romeu A. (2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics (PsyArXiv, 2024)

The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice - Fleury S; Nautiyal KM. (bioRxiv, 2024)

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. - Floris G; Dabrowski KR; Zanda MT; Daws SE. (2024)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study. - Enriquez-Geppert S; Krc J; O'Higgins FJ; Lietz M. (2024)

Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022). - Kopra EI; Penttinen J; Rucker JJ; Copeland CS. (2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. - Hooper J; Gyongyosi E; Hutchison K; Mueller R. (PsyArXiv, 2024)

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study - University Health Network; Toronto (ClinicalTrials.gov, 2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. (PsyArXiv, 2024)

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task. - Olami A; Peled-Avron L. (2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders - Valdez T; Patel V; Senesombath D; Hatahet-Donovan Z; Hornick MG. (Preprints.org, 2024)

Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases. - Szpręgiel I; Bysiek A. (2024)

Expanding the Therapeutic Horizons of Psilocybin in Mental Health. - Kargbo RB. (2024)

Human brain changes after first psilocybin use - Lyons T; Spriggs M; Kerkelä L; Rosas F; Roseman L; Mediano P; Timmermann C; Oestreich L; Pagni B; Zeifman R; Hampshire A; Trender W; et al. (bioRxiv, 2024)

A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics - Barnett BS. (medRxiv, 2024)

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study. - Véliz-García O; Domic-Siede M. (2024)

Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom. - Karthiyayini B; Kalyani NN; Gowdhami B; Muthuselvam M; Dharumadurai D. (2024)

Snapshot of 5-HT2A receptor activation in the mouse brain via IP1 detection - de la Fuente Revenga M; González-Maeso J. (bioRxiv, 2024)

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming. - Brownstien M; Lazar M; Botvinnik A; Shevakh C; Blakolmer K; Lerer L; Lifschytz T; Lerer B. (2024)

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. - Marwood L; Croal M; Mistry S; Simmons H; Tsai J; Young MB; Goodwin GM. (2024)

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2024)

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. - Imperio CG; Levin FR; Martinez D. (2024)

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. - Li JR; Chiang KT; Kao YC; Yu CL; Yang FC; Liang CS; Hsu TW. (2024)

Neuroprotective effects of psilocybin in a rat model of stroke. - Yu SJ; Wu KJ; Wang YS; Bae E; Chianelli F; Bambakidis N; Wang Y. (2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol - Pincombe J; Williams M; Carruthers S; Rossell S. (PsyArXiv, 2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol (PsyArXiv, 2024)

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. - Petridis PD; Grinband J; Agin-Liebes G; Kinslow CJ; Zeifman RJ; Bogenschutz MP; Griffiths RR; Ross S. (2024)

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. - Dahan JDC; Dadiomov D; Bostoen T; Dahan A. (2024)

Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex. - Ivan VE; Tomàs-Cuesta DP; Esteves IM; Luczak A; Mohajerani M; McNaughton BL; Gruber AJ. (2024)

Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications. - Junges LH; Müller-Santos M. (2024)

Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. - Choi C; Johnson DE; Chen-Li D; Rosenblat J. (2024)

From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice. - Schenberg EE. (PsyArXiv, 2024)

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. - Nadeem Z; Parker S; McGovern H; Oestreich LK (The Australian and New Zealand journal of psychiatry, 2024)

Artificial intelligence and psychedelic medicine. - Sarris J; Halman A; Urokohara A; Lehrner M; Perkins D (Annals of the New York Academy of Sciences, 2024)

What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study. - Masse-Grenier M; Chang SL; Bélanger A; Stephan JF; Hébert J; Deschamps P; Plourde L; Provost F; Farzin H; Fallu JS; Dorval M; P3A Research Group. (2024)

Impact of psilocybin on cognitive function: A systematic review. - Meshkat S; Tello-Gerez TJ; Gholaminezhad F; Dunkley BT; Reichelt AC; Erritzoe D; Vermetten E; Zhang Y; Greenshaw A; Burback L; Winkler O; Jetly R; et al. (2024)

From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice. (PsyArXiv, 2024)

Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex - Lane CP; Tarka VM; Valentin O; Lehmann A; Hamel E; de Villers-Sidani E. (bioRxiv, 2024)

Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats. - Fisher EL; Smith R; Conn K; Corcoran AW; Milton LK; Hohwy J; Foldi CJ. (2024)

Beyond the numbers: reimagining healing with psychedelics for eating disorders. - Lafrance A; Spriggs MJ; Gukasyan N; Peck SK (Journal of eating disorders, 2024)

What should constitute a control condition in psychedelic drug trials? - Colloca L; Fava M. (2024)

Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy. - Halman A; Conyers R; Moore C; Khatri D; Sarris J; Perkins D. (2024)

Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy. - Ordovich-Clarkson RD; Jabbour M; Pelayo DA; Lara D; La Croix S; Mumman M; Stukas S; Anderson R; Meraz D; Bangura A; Anderson B; Bamrud L; et al. (2024)

The Effects of Psilocybin on Shared Experience in Film Processing - Western University; Canada (ClinicalTrials.gov, 2024)

Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. - Meling D; Egger K; Aicher HD; Jareño Redondo J; Mueller J; Dornbierer J; Temperli E; Vasella EA; Caflisch L; Pfeiffer DJ; Schlomberg JT; Smallridge JW; et al. (2024)

Impact of Protonation Sites on Collision-Induced Dissociation-MS/MS Using CIDMD Quantum Chemistry Modeling. - Lee J; Tantillo DJ; Wang LP; Fiehn O. (2024)

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study. - Ellis S; Bostian C; Feng W; Fischer E; Schwartz G; Eisen K; Lean M; Conlan E; Ostacher M; Aaronson S; Suppes T. (2024)

Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity - Allohverdi S; Soltanzadeh M; Schmidt A; Charlton C; Hauke D; Karvelis P; Vollenweider F; Diaconescu A. (Research Square, 2024)

An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder - University of California; San Francisco (ClinicalTrials.gov, 2024)

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction. - Vamvakopoulou IA; Nutt DJ. (2024)

Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice - Abe Y; Sugiura Y; Maeda R; Taira S; Yoshida K; Ibi D; Moritoh S; Hashimoto K; Yagishita S; Tanaka KF. (bioRxiv, 2024)

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder. - Zhu X; Zhang C; Hellerstein D; Feusner JD; Wheaton MG; Gomez GJ; Schneier F. (2024)

Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment - Lazar M; Brownstien M; Botvinnik A; Shevakh C; Shahar O; Lifschytz T; Lerer B. (bioRxiv, 2024)

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. - Li LJ; Mo Y; Shi ZM; Huang XB; Ning YP; Wu HW; Yang XH; Zheng W. (2024)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans - Larsen K; Lindberg U; Ozenne B; McCulloch DE; Armand S; Madsen MK; Johansen A; Stenbæk DS; Knudsen GM; Fisher PM. (medRxiv, 2024)

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. - Erritzoe D; Barba T; Greenway KT; Murphy R; Martell J; Giribaldi B; Timmermann C; Murphy-Beiner A; Jones MB; Nutt D; Weiss B; Carhart-Harris R. (2024)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates the gabapentin-mediated analgesia - Askey T; Allen-Ross D; Lasrado R; Gilmour G; Hunt S; Tamagnini F; Ahmed M; Stephens G; Maiarú M. (Research Square, 2024)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. - Calder AE; Rausch B; Liechti ME; Holze F; Hasler G. (2024)

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study. - Rucker J; Butler M; Hambleton S; Bird C; Seynaeve M; Cheema S; Campbell-Coker K; Maggio C; Dunbar F; Lambru G; Matharu M. (2024)

Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus - University Hospital; Ghent (ClinicalTrials.gov, 2024)

CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality. - Gobbi G. (2024)

Psychedelic research at a crossroads. - Armstrong SB; Davis AK. (2024)

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents. - Werle I; Bertoglio LJ. (2024)

Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use. - Glynos NG; Baker A; Aday JS; Pouyan N; Barron J; Herberholz M; Kruger D; Boehnke KF. (2024)

Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress - Mageean S; Daniel A; Tai S. (Research Square, 2024)

Psychedelics as a potential treatment for tobacco use disorder: a systematic review. - Spoelstra SK; Schoevers RA; Venema SD; Knegtering H. (2024)

Exploring the regulatory framework of psychedelics in the US & Europe. - Behera HK; Joga R; Yerram S; Karnati P; Mergu T; Gandhi K; M S; Nathiya D; Singh RP; Srivastava S; Kumar S. (2024)

Less is more? A review of psilocybin microdosing. - Savides IA; Outhoff K. (2024)

New frontiers in the biosynthesis of psychoactive specialized metabolites. - Li G; Facchini PJ. (2024)

Psychedelic mushroom-containing chocolate exposures: Case series. - Gartner HT; Wan HZ; Simmons RE; Sollee DR; Sheikh S. (2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts. - Wilson-Poe A; Hoffman K; Pertl K; Luoma J; Bazinet A; Stauffer C; McCarty D; Korthuis P. (2024)

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. - Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C. (2024)

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. - Nicholas CR; Banks MI; Lennertz RC; Wenthur CJ; Krause BM; Riedner BA; Smith RF; Hutson PR; Sauder CJ; Dunne JD; Roseman L; Raison CL. (2024)

Refractory CRPS pain treated with psilocybin: A case report. - Jevotovsky DS; Chopra H; Wing C; Spotswood CJ; Castellanos J. (2024)

Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report. - Stephan JF; Karam S. (2024)

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner - Nikolic M; Mediano P; Froese T; Reydellet D; Palenicek T. (medRxiv, 2024)

Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review. - Thaoboonruang N; Lohitnavy M; Lohitnavy O. (2024)

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies. - Low ZXB; Ng WS; Lim ESY; Goh BH; Kumari Y. (2024)

Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment. - Anderson K; Elf P; Isham A. (2024)

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice. - Pohořalá V; Kuchař M; Spanagel R; Bernardi RE. (2024)

Psychoactive substances for the treatment of neuropsychiatric disorders. - Zhen Z; Sun X; Yuan S; Zhang J. (2024)

Fire Kasina advanced meditation produces experiences comparable to psychedelic and near-death experiences: A pilot study. - Woollacott M; Riddle J; Hermansson N; Sacchet MD; Ingram DM. (2024)

Commentary on Darke et al.: Expanded psychedelic access requires new safety monitoring systems. - Korthuis PT; Wilson-Poe AR; Black JC; Monte A (Addiction (Abingdon, England), 2024)

Psilocybin desynchronization persists in the human brain. - Rogers J. (2024)

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis. - Caspani G; Ruffell SGD; Tsang W; Netzband N; Rohani-Shukla C; Swann JR; Jefferies WA (Pharmacological research, 2024)

Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin? - Treviranus GRS. (2024)

Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders. - Loizaga-Velder A; Loizaga Pazzi A. (2024)

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis. - Smith CL; Sackett N; Stark BC; Dinh V; Romesburg EW; Roll J (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Psilocybin for Treatment of Obsessive Compulsive Disorder - University of Arizona (ClinicalTrials.gov, 2024)

Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects. - Martial C; Carhart-Harris R; Timmermann C. (2024)

Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report. - Federico S; Geo M; Entela M; Bachmann S; Elisa R; Silvio C; Zoë D; Louise P; Gabriel T; Joël B; Daniele Z. (2024)

The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance - Yoo M; Sakopoulos S. (Authorea Preprints, 2024)

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment]. - Jungwirth J; Bavato F; Quednow BB. (2024)

The role of psilocybin in depressive disorders. - Najib J. (2024)

A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis - Tsang V. (2024)

Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations - Tsang V; Roney C. (2024)

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting - Klučková T; Nikolič M; Tylš F; Viktorin V; Vejmola Č; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Zach P; Hájková K; et al. (medRxiv, 2024)

Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse: A Cautionary Tale. - Frye MA; Singh B; Breitinger SA; Oesterle TS. (2024)

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study - Jensen ME; Stenbæk DS; Messell CD; Poulsen ED; Varga TV; Fisher PM; Nielsen MKK; Johansen SS; Volkow ND; Knudsen GM; Fink-Jensen A. (Research Square, 2024)

Classic psychedelics and the treatment for alcoholism. - Lodetti G; de Bitencourt RM; Rico EP. (2024)

Identifying Three Psilocybin Use Patterns by Frequency and Quantity. - Gray BA; Bolts OL; Fidler D; Prince M. (2024)

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. - Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS. (2024)

Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience. - Kargbo RB. (2024)

Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine. - Kargbo RB. (2024)

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA. - Calder AE; Hasler G. (2024)

A virtual clinical trial of psychedelics to treat patients with disorders of consciousness - Alnagger NL; Cardone P; Martial C; Sanz Perl Y; Mindlin I; Sitt JD; Roseman L; Carhart-Harris R; Nutt D; Mallaroni P; Mason NL; Ramaekers JG; et al. (bioRxiv, 2024)

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. - Salvetti G; Saccenti D; Moro AS; Lamanna J; Ferro M. (2024)

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review. - Kim A; Halton B; Shah A; Seecof OM; Ross S. (2024)

A24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) - Clairvoyant Therapeutics (ClinicalTrials.gov, 2024)

Prevalence and Correlates of Psychedelic Use in Poland: A Study on a Representative Sample of Polish Adults - Holas P; Kaminska J. (Research Square, 2024)

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis. - Chen MH; Cheng SL; Kao YC; Tseng PT; Hsu CW; Yu CL; Yang FC; Thompson T; Hsu TW; Liang CS. (2024)

Psilocybin for clinical indications: A scoping review. - Madden K; Flood B; Young Shing D; Ade-Conde M; Kashir I; Mark M; MacKillop J; Bhandari M; Adili A. (2024)

Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire. - Hovmand OR; Madsen MK; Fisher PM; Stenbæk DS. (2024)

Ayahuasca for the treatment of alcohol use disorder. - Marinho EAV; Serra YA; Oliveira-Lima AJ; Marcourakis T; Berro LF. (2024)

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) - Sheppard Pratt Health System (ClinicalTrials.gov, 2024)

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial - Ottawa Hospital Research Institute (ClinicalTrials.gov, 2024)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium - Vella Y; Syrova K; Petruskova A; Koutrouli I; Kutna V; Pala J; Nikolic M; Sichova K; Mazoch V; Jurok R; Kuchar M; Bendova Z; et al. (bioRxiv, 2024)

Letter to editor regarding "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis". - Yang X; Kuang W. (2024)

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms - Brugmann University Hospital (ClinicalTrials.gov, 2024)

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. - VanderZwaag B; Garcia-Romeu A; Garcia-Barrera MA. (2024)

Rapid, biochemical tagging of cellular activity history in vivo. - Zhang R; Anguiano M; Aarrestad IK; Lin S; Chandra J; Vadde SS; Olson DE; Kim CK. (2024)

Psilocybin-assisted therapy and HIV-related shame. - Mehtani NJ; Johnson MO; Hendricks PS; Mitchell J; Anderson BT. (2024)

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study - Véliz-García O; Domic M. (Research Square, 2024)

Is it now time to prepare psychiatry for a psychedelic future? - Nutt D; Crome I; Young AH. (2024)

Psychedelic-assisted psychotherapy: where is the psychotherapy research? - Aday JS; Horton D; Fernandes-Osterhold G; O'Donovan A; Bradley ER; Rosen RC; Woolley JD (Psychopharmacology, 2024)

Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness. - Mograbi DC; Rodrigues R; Bienemann B; Huntley J (Current neurology and neuroscience reports, 2024)

CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS. - Kaiserman A; Vanderjist L; Kornreich C. (2024)

Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors. - Woodburn SC; Levitt CM; Koester AM; Kwan AC. (2024)

Psilocybin in pharmacotherapy of obsessive-compulsive disorder. - Owe-Larsson M; Kamińska K; Buchalska B; Mirowska-Guzel D; Cudnoch-Jędrzejewska A. (2024)

How psilocybin affects the brain. - O'Leary K. (2024)

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users - david J; Berkovich-Ohana A; Dor-Ziderman Y. (PsyArXiv, 2024)

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users (PsyArXiv, 2024)

Psilocybin for the Treatment of Major Depressive Disorder - Washington University School of Medicine (ClinicalTrials.gov, 2024)

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol - Butler M; Bird C; Maggio C; Durden A; Modlin N; Campbell-Coker K; Edwards M; Pick S; Millman LM; Lowery E; Bhagavan C; Kanaan R; et al. (Wellcome Open Res, 2024)

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα - Viohl N; Zanjani AAH; Khandelia H. (bioRxiv, 2024)

Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants. - Bhagavan C; Kanaan R; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Oliver G; Mayne D; McKernon D; et al. (2024)

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges. - Gomez-Escolar A; Folch-Sanchez D; Stefaniuk J; Swithenbank Z; Nisa A; Braddick F; Idrees Chaudhary N; van der Meer PB; Batalla A. (2024)

Wood-loving magic mushrooms from Australia are saprotrophic invaders in the Northern Hemisphere. - McTaggart AR; Scarlett K; Slot JC; Barlow C; Appleyard C; Gardiner DM; Fechner N; Tilden J; Hass D; Voogelbreinder S; Lording WJ; Lloyd RA; et al. (2024)

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. - de la Salle S; Kettner H; Thibault Lévesque J; Garel N; Dames S; Patchett-Marble R; Rej S; Gloeckler S; Erritzoe D; Carhart-Harris R; Greenway KT. (2024)

Psilocybin desynchronizes the human brain. - Siegel JS; Subramanian S; Perry D; Kay BP; Gordon EM; Laumann TO; Reneau TR; Metcalf NV; Chacko RV; Gratton C; Horan C; Krimmel SR; et al. (2024)

Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. - Do A; Michaud V; Stephan JF; Moreau M; Benoît É; Bérubé FA; Bibaud-De Serres A; Taillefer A; Vincent P. (2024)

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study - Anders Fink-Jensen; MD; DMSci (ClinicalTrials.gov, 2024)

Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions - Nogueira M; García-Hernández S; Roberto GS; Marques LZ. (medRxiv, 2024)

Quantitative Natural Language Processing Markers of Psychoactive Drug Effects: A Pre-Registered Systematic Review - Ahuja S; Zaher F; Palaniyappan L. (Research Square, 2024)

Psilocybin fungi microdose treatment in major depressive disorder: a case report - Zarankin M; Pellegrini MS; Zenteno F. (2024)

Psilocybin for the treatment of Alzheimer's disease. - Zheng S; Ma R; Yang Y; Li G. (2024)

Magic of the Mushrooms: Effects of Psilocybin Decriminalization. - Bhave A. (2024)

Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits - West CL; Imai F; Bastos G; Hornick MA; Rachmany L; Duran A; Nadeem S; Ricci D; Rader Groves AM; Wargo JA; Van Leeuwen N; Sershen H; et al. (bioRxiv, 2024)

Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method. - Khajavinia A; Michel D; Ezeaka UC; Purves RW; Laprairie RB; El-Aneed A. (2024)

Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection. - Yao Y; Zhang YZ; Liang JQ; Liu F; Li ZF; Li HJ; Xu F. (2024)

Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. - Kolasa M; Nikiforuk A; Korlatowicz A; Solich J; Potasiewicz A; Dziedzicka-Wasylewska M; Bugno R; Hogendorf A; Bojarski A; Faron-Górecka A. (2024)

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. - Poulin JM; Bigford GE; Lanctôt KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; Husain MI; et al. (2024)

Effects of psilocybin on body weight, body composition, and metabolites in male and female mice. - Shakir J; Pedicini M; Bullock BC; Hoen PW; Macias LK; Freiman J; Pletnikov MV; Tamashiro KLK; Cordner ZA. (2024)

Bridging Psilocybin-Induced Changes in the Brain's Dynamic Functional Connectome With an Individual's Subjective Experience. - Singleton SP; Kuceyeski A. (2024)

Potential Differences in Psychedelic Actions Based on Biological Sex. - Shadani S; Conn K; Andrews ZB; Foldi CJ (Endocrinology, 2024)

Your brain on shrooms - how psilocybin resets neural networks. - Kozlov M. (2024)

Treating Anxiety and Depression With Psilocybin Therapy. - Hanstein AP; Felchlin C. (2024)

The Black Book of Psychotropic Dosing and Monitoring. - DeBattista C; Schatzberg AF. (2024)

Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis. - Bader H; Farraj H; Maghnam J; Abu Omar Y. (2024)

Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming - Brownstien M; Lazar M; Botvinnik A; Shevakh C; Blakolmer K; Lerer L; Lifschytz T; Lerer B. (bioRxiv, 2024)

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models. - Foldi CJ; Liknaitzky P; Williams M; Oldfield BJ. (2024)

Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study. - Peck SK; Shao S; Gruen T; Yang K; Babakanian A; Trim J; Finn DM; Kaye WH. (2024)

Innovative and Emerging Treatments for Anorexia Nervosa. - Downey AE; Gorrell S. (2024)

The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world. - Lake S; Lucas P. (2024)

Psilocybin and 2C-B at Encoding Distort Episodic Familiarity. - Doss MK; Mallaroni P; Mason NL; Ramaekers JG. (2024)